Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that horizontal sections of scalp biopsy specimens provide more diagnostic information for male pattern androgenetic alopecia than vertical sections and can predict hair regrowth potential following topical minoxidil therapy.

This study found that specific genetic markers near the androgen receptor gene are significantly more common in men with male pattern baldness, suggesting a genetic component in its development.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study found that glycolytic metabolism and lactate production are crucial for hair follicle stem cell activation, and manipulating these processes can stimulate the hair cycle.

This study found that the prevalence of androgenetic alopecia increases with age among both men and women in Maryborough, Australia, with 57% of women and 73.5% of men aged 80 and over affected.

Male pattern baldness is largely genetic, linked to the androgen receptor gene, and may relate to certain health issues.

This study found no significant genetic association between the 5α-reductase enzyme genes and male pattern baldness, suggesting a polygenic etiology rather than simple inheritance.

This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.

This study found that MPEG-dihexPLA micelles significantly improved the skin deposition of tacrolimus compared to a marketed ointment, suggesting better targeted delivery with reduced systemic absorption.

This review discusses the histopathology of male-pattern baldness and highlights ongoing disputes over several aspects, including sebaceous gland size and follicle loss, reporting no new clinical findings.

This study observed that autologous platelet-rich plasma treatment improved hair count and density in areas with androgenetic alopecia compared to placebo, with differing outcomes based on the PRP collection device used.

This study found that econazole nitrate delivered via MPEG-dihexPLA micelles significantly increased skin deposition compared to Pevaryl® cream, potentially enhancing drug bioavailability and clinical efficacy.

This study found that methylprednisolone can block IgG-induced keratinocyte detachment in an animal model of pemphigus vulgaris, potentially by increasing the synthesis and modifying adhesion molecules.

In this study, the researchers observed that male pattern alopecia is characterized by miniature follicles, enlarged sebaceous glands, and an increased number of mast cells, without significant abnormalities in enzyme activity.

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.

This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.

This study found that men with common male pattern baldness received less favorable initial social perceptions, including lower ratings of physical attractiveness, than their nonbalding counterparts.

This study found that prostaglandin metabolism enzymes are present in human hair follicles, suggesting a potential role in hair growth and differentiation, with some expression differences between men and women.

This study identified 63 genetic loci associated with male-pattern baldness, uncovering genes and pathways that may help develop treatments and suggesting its connection to other human conditions.

This review concluded that FDA-cleared low-level laser therapy devices are safe and effective for patients with male and female pattern hair loss who do not respond to or tolerate standard treatments.

This study found that male pattern baldness in European males is strongly heritable and associated with genetic markers linked to earlier puberty, bone density, and pancreatic function.

This article reviews current knowledge on the causes, diagnosis, and medical treatments for androgenetic alopecia, particularly in men, and reports no new findings.

This genome-wide association study identified 71 genetic loci linked to male pattern baldness, with 30 novel loci, explaining 38% of the risk and suggesting shared pathways with lifespan and cancer traits.

This study found no support for the idea that male-pattern baldness in female-to-male transsexuals indicates an increased risk of coronary heart disease through androgenic effects on classic risk factors.

This study suggests that a 1,550-nm fractional erbium-glass laser may stimulate hair growth in both an alopecia mouse model and human subjects with male pattern hair loss, though further research is needed to determine its clinical applications.

In this study, 42% of healthy men aged 18-49 showed moderate to extensive male pattern hair loss, with prevalence increasing significantly with age.

This study found that a genetic test using 5 to 20 SNPs can predict male pattern baldness with variable accuracy in European men, especially those aged 50 and older.

High testosterone to epitestosterone ratio in hair could predict male-pattern baldness.

This article updates a diagnostic tool (SALT II) for assessing hair loss by adding more precise measurements of scalp surface area, particularly useful for various types of alopecia.

This review addresses the limited efficacy of current treatments for male pattern baldness and explains that emerging genetic insights could lead to more effective future therapies.